[Skip to Content]
[Skip to Content Landing]
Editorial
October 2018

Cervical Cancer Screening—Moving From the Value of Evidence to the Evidence of Value

Author Affiliations
  • 1Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco
  • 2Department of Epidemiology & Biostatistics, University of California, San Francisco
  • 3Center for Healthcare Value, University of California, San Francisco
JAMA Intern Med. 2018;178(10):1293-1295. doi:10.1001/jamainternmed.2018.4282

Widespread implementation of cytology-based screening programs has resulted in marked declines in cervical cancer incidence and mortality in the United States. Nonetheless, an estimated 13 240 women will be diagnosed with cervical cancer in 2018, and 4170 will die from the disease.1 It is likely that a sizable proportion of these women will not have been appropriately screened.2

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×